United Homes Group stock plunges after Nikki Haley, directors resign
SOUTH SAN FRANCISCO - Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), whose stock has surged over 136% in the past six months according to InvestingPro data, announced interim data from its Phase 1b/2 clinical trial evaluating ciforadenant in combination with ipilimumab and nivolumab as a first-line treatment for metastatic renal cell carcinoma (RCC).
The data, presented at the European Society for Medical Oncology Congress 2025 in Berlin, showed that the triplet therapy demonstrated feasibility and tolerability in the 50-patient trial. The deep response rate was 34%, showing improvement compared to historical data for ipilimumab and nivolumab alone, though not yet statistically significant. With a strong financial health score of 2.66 on InvestingPro and a current ratio of 8.91, the company appears well-positioned to continue its clinical development programs.
The objective response rate reached 46%, including two complete responses and 21 partial responses, with a median progression-free survival of 11.04 months. Nineteen patients with stable or responding disease remain on therapy with potential to achieve deep responses.
Dr. Katy Beckermann, Director of Genitourinary Cancer Research at Tennessee Oncology and member of the Kidney Cancer Research Consortium, presented the findings. The trial enrolled patients with unfavorable disease characteristics, with only 54% having had prior nephrectomy compared to the typical 75-85% in similar studies.
"The treatment was well-tolerated, in-line with the safety profile of combination treatment with ipilimumab and nivolumab," noted Dr. Beckermann in the presentation.
Ciforadenant is an investigational oral checkpoint inhibitor designed to block adenosine binding to immune cells in the tumor microenvironment, potentially preventing tumors from evading immune system attack.
The trial is being conducted in collaboration with the Kidney Cancer Research Consortium. According to the press release statement, longer follow-up with patients still on therapy is needed to determine the potential benefit of blocking adenosine signaling in RCC treatment. With analyst price targets ranging from $11 to $24 and the company’s next earnings report scheduled for October 30, 2025, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed research reports.
In other recent news, Corvus Pharmaceuticals reported its second-quarter 2025 earnings, revealing an earnings per share (EPS) of -$0.10, which exceeded the forecasted -$0.13. This represents a 23.08% positive surprise, indicating stronger-than-expected financial performance. Additionally, Barclays initiated coverage on Corvus Pharmaceuticals with an Overweight rating and set a price target of $16.00, highlighting a positive risk-reward profile for the company’s ITK inhibitor soqueltinib (CPI-818) ahead of upcoming data on atopic dermatitis.
In corporate developments, Corvus Pharmaceuticals announced the appointment of David Moore to its board of directors. Moore, who is also the Executive Vice President of US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., brings 27 years of industry experience to the company. His expertise spans strategy, commercial operations, market access, and business development. Moore will also serve on the board’s Compensation Committee and Nominating and Corporate Governance Committee. These recent developments reflect Corvus Pharmaceuticals’ ongoing strategic initiatives and leadership expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.